Myelin maturation failure and oligodendrocyte precursor loss underlie default mode network disruption in a humanized APP knock-in model of Alzheimer’s disease
Findings identify disruption of myelin–network coupling as a potential mechanism underlying the biphasic evolution of network dysfunction in Alzheimer’s disease and suggest that restoring oligodendroglial function may provide cognitive benefits beyond those of amyloid-targeting strategies.
Abstract
Alzheimer’s disease disrupts large-scale brain networks before cognitive symptoms emerge, yet the mechanisms underlying this progression remain unclear. In humans, default mode network (DMN) connectivity follows a biphasic trajectory, with a transition from hypersynchrony to hyposynchrony associated with increasing amyloid burden and cognitive decline. Using a mouse model of amyloidopathy that recapitulates this trajectory, we show that amyloid-β accumulation arrests normal age-dependent myelin maturation, followed by progressive myelin loss and oligodendroglial dysfunction. In healthy animals, regional myelin coverage predicts DMN strength, revealing a coupling that is disrupted by amyloidopathy. Notably, DMN hypersynchrony emerges before substantial amyloid accumulation or overt myelin loss, whereas subsequent oligodendroglial dysfunction and myelin loss coincide with DMN disintegration and cognitive deficits. These findings identify disruption of myelin–network coupling as a potential mechanism underlying the biphasic evolution of network dysfunction in Alzheimer’s disease and suggest that restoring oligodendroglial function may provide cognitive benefits beyond those of amyloid-targeting strategies.
In Alzheimer’s Disease (AD) the default mode network (DMN) exhibits selective vulnerability to functional decline and amyloid beta (Aβ) plaques in early AD. DMN vulnerability may simply be the result of Aβ accumulation. Alternately, Aβ may unmask an intrinsic susceptibility of DMN circuits. Should DMN vulnerability per...
Samuel J. Brunwasser, James N. McGregor, Kiran Bhaskaran-Nair et al.· Nature Communications· 0 citations
A comprehensive overview of myelin structure and function is provided, evaluating the potential of tracking myelin changes as early diagnostic biomarker for AD and its critical potential as a novel therapeutic target for AD and other neurodegenerative conditions.
Li-Hong Huang, Peng Cheng, Guang-Dong Liu et al.· MedComm· 0 citations
Cognitive decline in aging impacts quality of life, for which therapeutic interventions are lacking. Why some individuals experience more severe cognitive decline with aging is unclear. Here we uncover a role for the brain’s myelin-forming cells—oligodendrocytes—in explaining this variance. By investigating neuropathol...
Georgina A. Craig, Emeric Merour, L. Seeker et al.· Nature Medicine· 0 citations
Evidence supports a shift from a linear amyloid model to a multidimensional framework and offers promise for early detection, risk stratification, and personalized multi-target therapies in AD.
C. D. Souza, Shiva Murthy Nanjundappa, N. Murali· International Journal of Bas...· 0 citations
Lower static connectivity across multiple large-scale networks was associated with faster longitudinal tau accumulation and, selectively in individuals with elevated amyloid burden, with accelerated cognitive decline, and these associations were not observed for time-varying connectivity.
Mohammadali Javanray, Jonathan Gallego-Rudolf, Y. Yakoub et al.· Research Square· 0 citations
Abstract BACKGROUND Tau pathology in Alzheimer's disease (AD) propagates along the brain's connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to tau‐harboring epicenters. METHODS One hundred thirty‐one amyloid‐posit...
Lukas Frontzkowski, Sebastian N. Roemer-Cassiano, Johannes S. Gnörich et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.